Download the ESMO 2012 Abstract Book - Oxford Journals

emaining receiving either CAV or topotecan based CT, with an RR of 50%. In the
3rd-line, 35 pts (28%) were re-challenged with CT similar to a prior regimen. Only
27 pts (22%) received 3 distinct lines of CT. Median progression free survival (PFS)
in the 1st, 2nd and 3rd-lines were: 9.0, 4.6 and 2.0 months respectively. The RR in
the 3rd-line was 17%, with no complete responses. Median 3rd-line OS was 4.8
months. Factors associated with longer OS were: normal baseline serum LDH (p =
0.02), response to 2nd-line CT (p = 0.04) and PFS >3 months after 2nd-line CT (p =
0.05). Age, sex, initial disease stage, and CT re-challenges did not predict longer
survival. After the 3rd-line, 35 pts received further CT.
Conclusions: In 5 cancer centres, over 10 years, few SCLC pts received 3 lines of CT.
Most who received 3 lines had been re-challenged with a similar regimen at least
once. OS and RR in the 3rd-line are modest. Lack of response to, or progression after
2nd-line CT may predict particular lack of benefit in the 3rd-line. Prospective
research in this area is needed.
Disclosure: All authors have declared no conflicts of interest.
1526P HYPONATRAEMIA AS A MARKER OF INFERIOR OUTCOMES
IN SMALL CELL LUNG CANCER (SCLC)
N.J. Coleman 1 , J. Clince 2 , W.M. Grogan 2 , O.S. Breathnach 1
1 Medical Oncology, Beaumont Hospital Cancer Centre, Dublin, IRELAND,
2 Medical Oncology, Beaumont Hospital, Dublin, IRELAND
Introduction: Small cell lung cancer (SCLC) represents approximately 15% of all
lung cancer diagnoses and is reducing in incidence. Hyponatremia is a common and
debilitating electrolyte disorder, frequently documented in SCLC. Its occurrence is
typically attributed to paraneoplastic syndrome- induced syndrome of inappropriate
antidiuretic hormone hypersecretion (SIADH). The influence of hyponatremia on
the survival of patients with lung cancer remains poorly understood. Aim: The aim
of this retrospective study is to investigate clinical features and the prognostic value
of hyponatremia in an unselected Irish patient population with small cell lung cancer
(SCLC) with limited disease (LD) and extensive disease (ED).
Method: The data of patients diagnosed with SCLC in Beaumont hospital over a
3-year period was analysed retrospectively. Patients were identified from analysis of
all lung cancers biopsies via the pathology department databank. Data was collected
from clinical notes on identified patients including clinical performance status, serum
sodium values, disease stage, chemotherapy regimens and response, radiotherapy,
palliative care input and survival.
Results: 48 patients (22 male, 26 female) with a median age 64 yrs (range 41-87yrs),
29.17%(n = 14) with limited stage were identified. The standard chemotherapy was
carboplatin–etoposide. 7 patients received 2 nd line treatment with irinotecan. 16.6%
patients did not receive chemotherapy (n = 8) due to poor performance status.
Hyponatraemia (plasma sodium [P-Na]